Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BARCELONA, SPAIN--(Marketwire - Oct 25, 2012) - Techno-College Booth 005; EACTS Booth 92/93 - BioVentrix, the developer of minimally invasive heart failure therapies, today introduced the...
-
BARCELONA, ESPAÑA--(Marketwire - Oct 25, 2012) - Stand 005 Techno-College; Stand 92/93 de EACTS - BioVentrix, el desarrollador de terapias mínimamente invasivas para el tratamiento de...
-
BARCELONA, SPAIN--(Marketwire - Oct 25, 2012) - Techno-College-Stand 005; EACTS-Stand 92/93 – BioVentrix, der Entwickler von minimalinvasiven Herzinsuffizienztherapien, stellte heute das...
-
BARCELONA, SPAIN--(Marketwire - Oct 25, 2012) - Stand Techno-College005; stand EACTS 92/93 - BioVentrix, azienda operante nel settore dello sviluppo di terapie per l'insufficienza cardiaca...
-
BARCELONA, SPAIN--(Marketwire - Oct 25, 2012) - Techno-College Stand 005; EACTS Stand 92/93 - BioVentrix, de ontwikkelaar van minimaal invasieve hartfalen therapieën, introduceerde vandaag...
-
BARCELONA, SPAIN--(Marketwire - Oct 25, 2012) - Stand Techno-College 005 ; Stand EACTS 92/93 - BioVentrix, le développeur de traitements mini-invasifs contre les insuffisances...
-
SAN RAMON, CA--(Marketwire - Oct 23, 2012) - Results from a clinical abstract to be presented at the TCT 2012 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the...
-
SAN RAMON, CA--(Marketwire - Oct 3, 2012) - BioVentrix, the developer of minimally invasive therapies for the treatment of heart failure, today announced the initiation of a Phase II clinical trial...
-
SAN RAMON, CA--(Marketwire - Jun 18, 2012) - BioVentrix, the developer of minimally invasive therapies for the treatment of heart failure, announced the election of Mr. George J. Fazio and Mr....
-
PARIS--(Marketwire - May 14, 2012) - BioVentrix, the developer of minimally invasive therapies for the treatment of heart failure, was selected to present at EuroPCR, the annual meeting of the...